Image: Assembly Biosciences
Highlighting Anomalies Amongst the Week’s Biggest Gainers, Losers, & Volume Leaders.
by Christian Galatti (Phase 4 Research)
Assembly Biosciences…+73% for the Week.
The Company Becomes Event Driven.
From 2016 to 2018 Assembly Biosciences could do no wrong (see chart.) Getting closer to a cure for Hepatitis B gave the stock momentum that lasted, and lasted and lasted. Allowing them to raise $144M last July at $36 on the way down when the trial data became less sublime. A raise that paid for research that was meant to stop the bleeding. Baird stated in an initiation piece in August 2018 at $38 that ASMB would almost double to $74 shortly. While not understanding the true market forces that would take the stock straight to $9.
Baird Initiates Coverage On Assembly Biosciences with Outperform Rating,
Announces $74 Price Target, August 08, 2018
While not a cure, Assembly Bio’s product does work. It works well enough that it may be the best thing out there. Clinical data showing that the virus was reduced in just two weeks was good enough for the stock to make the biggest gainer list this week with a 72% gain after hitting lows.
Shares of Assembly Biosciences (NASDAQ:ASMB) gained over 41% today after the company announced an update on its hepatitis B virus (HBV) programs.
The first update, from a phase 2a study evaluating the lead drug candidate ABI-H0731, suggests that the pipeline asset is effective in reducing DNA and RNA signatures of the virus. The second update, from a phase 1b study of a next-generation drug candidate named ABI-H2158, suggests that the asset can reduce the activity of the virus after just 14 days.
ASMB has become an event driven stock. More data is coming out on November 11th. An event that’s worth the following quote as the story is about to continue through the end of the year.
If either of Assembly’s HBV drugs becomes modestly successful, this company’s recent $381 million market cap will more than double, more than once. We’ll get a clearer picture when the company describes its poster presentations at AASLD on Monday, Nov. 11, 2019.
After burning through $46 million in the first half of 2019, the company finished June with $174 million in cash and securities. That’s only enough to fund the company’s expanding operations into the beginning of 2021, which means a dilutive secondary offering is probably right around the corner.
- Safety and Antiviral Activity of Assembly Biosciences’ First and Second Generation Core Inhibitor Candidates In the Treatment of Chronic Hepatitis B to be Featured in a Late Breaking Session at AASL
- Phase 2a studies of ABI-H0731 + nucleos(t)ide analogs (Nrtl) in HBeAg+ patients show faster and deeper declines in HBV DNA and RNA with combination than Nrtl alone, as well as subsequent declines in the surrogate markers of cccDNA with long-term treatment
- Potent antiviral activity observed in first cohort of HBeAg+ patients treated in 14-day monotherapy study of ABI-H2158
- Company to host conference call Monday, November 11, 2019 at 8:30am ET
(Analyst Disclosures: None, no ownership or relationship.)
Risk was on this past week, on the back of the promise of the rumor of a rumor of a seed stage of a trade deal.
Equities Contributor: Chris Lahiji
Source: Equities News